Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Aegerion Pharmaceuticals (AEGR) to Acquire Myalept from AstraZeneca (AZN) for $325M
November 6, 2014 6:33 AM ESTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) entered into a definitive agreement with AstraZeneca (NYSE: AZN) to acquire Myalept, an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.
Myalept is the first and only product approved in the US for the... More
